Go to the top

Understanding Intracranial Atherosclerosis Disease (ICAD) and High Risk of Second Stroke

Posted on November 24, 2010

Demetrius Lopes, MD, endovascular-trained neurosurgeon along with his neurological colleagues at Rush University Medical Center in Chicago announced they are the only team  in the Midwest selected to participate in the pivotal MoSIS Trial.  The Mechanisms of Stroke in Intracranial Stenosis (MoSIS) trial is designed to allow stroke experts, like Dr. Lopes, to study and quantify the levels of stroke risk and stroke recurrence in patients with narrowed brain arteries.   Narrowed brain arteries caused by ICAD are the most common cause of stroke today.

Using non-invasive imaging tests such as ultrasound and quantitative magnetic resonance angiography (QMRA) study investigators, including Dr. Lopes will be able to closely assess each participating patient’s blood vessels and arteries.  “We will be able to examine blood flow changes caused by the build-up of fat plaques in the blood vessel walls ” explains Dr. Lopes.  “Understanding the exact mechanism for reduced blood supply to the brain in patients with ICAD will allow us to develop more specific and effective therapies.  We also hope this study provides us additional information to identify which patients are at greatest risk for stroke.”

The MoSIS study is a supplementary study to the Stenting versus Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial, which is the first study to look at the long-term benefits of inserting stents to open clogged arteries in the brain. Stroke experts from Rush along with researchers from the University of Miami will evaluate six specific mechanisms of stroke in the medically-treated subjects from the SAMMPRIS trial. 

To be eligible for the MoSIS or SAMMPRIS trials, patients must be between the ages of 30 and 80 years, have had a stroke or TIA within 30 days, and have stenosis (narrowing) of a major intracranial artery (blood vessel in the brain).

Questions regarding the MoSIS trial can be submitted to Dr. Lopes by replying below or through email at info@ChicagoStrokeMD.com